📣 Help Shape the Future of UKRI's Gateway to Research (GtR)

We're improving UKRI's Gateway to Research and are seeking your input! If you would be interested in being interviewed about the improvements we're making and to have your say about how we can make GtR more user-friendly, impactful, and effective for the Research and Innovation community, please email gateway@ukri.org.

Non-trough adalimumab and certolizumab drug levels associated with a therapeutic EULAR response in adherent patients with rheumatoid arthritis. (2023)

First Author: Hum RM

Attributed to: Maximising Therapeutic Utility for Rheumatoid Arthritis using genetic and genomic tissue responses to stratify medicines. funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1093/rheumatology/keac564

PubMed Identifier: 36190343

Publication URI: http://europepmc.org/abstract/MED/36190343

Type: Journal Article/Review

Volume: 62

Parent Publication: Rheumatology (Oxford, England)

Issue: 6

ISSN: 1462-0324